• 1
    Shick RM, Baggenstoss AH, Fuller BF, Polley HF. Effects of cortisone and ACTH on periarteritis nodosa and cranial arteritis. Mayo Clin Proc 1950; 25: 4924.
  • 2
    Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497504.
  • 3
    Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villalta J, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis: influence of corticosteroid treatment. Arthritis Rheum 1989; 32: 88493.
  • 4
    Cid MC, Cebrian M, Font C, Coll-Vinent B, Hernandez-Rodriguez J, Esparza J, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte–endothelial cell interactions. Arthritis Rheum 2000; 43: 18494.
  • 5
    Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997; 99: 284250.
  • 6
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 26171.
  • 7
    Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatica: clinical and biopsy findings. Ann Intern Med 1972; 77: 84552.
  • 8
    Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002; 47: 2935.
  • 9
    Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932; 7: 7001.
  • 10
    Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: results in fifty-five cases in which lesion was proved at biopsy. JAMA 1957; 163: 8217.
  • 11
    Lie JT, Brown AL Jr, Carter ET. Spectrum of aging changes in temporal arteries: its significance, in interpretation of biopsy of temporal artery. Arch Pathol 1970; 90: 27885.
  • 12
    Esteban MJ, Font C, Hernandez-Rodriguez J, Valls-Sole J, Sanmarti R, Cardellach F, et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty-eight patients. Arthritis Rheum 2001; 44: 138795.
  • 13
    Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 130918.
  • 14
    Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 10614.
  • 15
    Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294301.